Prostate Cancer

The technique fails to demonstrate benefits for prostate cancer recurrence and metastases.

The researchers also found evidence supporting the role of germline variation in healthcare disparities related to prostate cancer.

“Instead of just offering a select-few treatment options, ideally you would like to be able to offer patients a whole menu of treatments and have an educated conversation regarding the risks and benefits for each of these treatment options," says Rian Dickstein, MD.

The FDA approved relugolix in December 2020 for the treatment of patients with advanced prostate cancer.

The research involved examining circulating markers of inflammation in patients with prostate cancer receiving androgen-deprivation therapy.

Because of the limitations of the research, the findings need to be considered with caution, said Lourdes Guerrios-Rivera, MD, MSc.

Urologist Adam J. Gadzinski, MD, MS, shares his excitement about the dawn of the precision medicine era in prostate cancer.

The researchers recommend patient counseling on these side effects and routine monitoring of cognitive function in patients receiving ADT.

Declan G. Murphy, MB BCh, discusses how PSMA PET/CT imaging often leads to the upstaging of a patient’s prostate tumor, as well as how the novel technique lowers the rate of equivocal findings.

The approval of the GnRH receptor antagonist is based on data from the phase 3 HERO study.

Treatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.

Murphy shares the backstory of how PSMA PET/CT imaging has emerged as a major advancement in the prostate cancer armamentarium.

The new drug application for 18F-DCFPyL is supported by results from the OSPREY and CONDOR trials.

Olaparib has "ushered in the era of precision medicine in prostate cancer," said Maha Hussain, MD.

Experts in prostate cancer, bladder cancer, kidney stones, OAB/incontinence, BPH, and sexual dysfunction recap all the key advances from 2020.

"As we slowly move toward the promise of precision medicine, it is important to understand fully this concept and the importance of testing and how it is to be used for diagnosis, management, and risk assessment," writes Raoul S. Concepcion, MD, FACS.

“Further prospective studies are warranted to identify potential mechanisms and to develop strategies that include a fall risk assessment tool to examine the risk factors for falls or fracture,” the authors wrote.

"Despite some heterogeneity in the type and frequency of testing during the surveillance period, these results provide reassurance and increased confidence in the safe utilization of AS protocols for men with low-risk GG1, and selected GG2, prostate cancer," Mian writes.

At a median follow-up of 15 years, the pooled analysis showed statistically significant improvements with adjuvant ADT over neoadjuvant ADT in biochemical failure, distant metastasis, and progression-free survival rates.

The vaccine RV001 targets RhoC, a small GTPase that is overexpressed in advanced solid tumors.

Hear from key opinion leaders in the urology space as they discuss 3 complex cases across the multidisciplinary approach.

SpaceOAR Vue Hydrogel, a radiopaque perirectal spacer for radiation therapy, is now available in the United States for use in patients with prostate cancer receiving radiotherapy.

"If your practice does not closely monitor patients and send them for early salvage radiotherapy when their PSA is 0.1 or 0.2 ng/mL, it is likely that adjuvant radiotherapy is superior," Daniel E. Spratt, MD, writes.

Christopher P. Evans, MD, and J. Brantley Thrasher, MD, conclude an in-depth discussion on active surveillance in men with low-risk prostate cancer.

In this video, Samuel J. Peretsman, MD, also discusses his experience with robotic prostatectomy following HIFU.

Christopher P. Evans, MD, discusses his active surveillance protocol with J. Brantley Thrasher, MD.

FoundationOneLiquid CDx will identify HRR alterations, such as BRCA1, BRCA2, and ATM, that make a patient eligible for olaparib.